​According to a report from KHL insider Jeremy Garrett, CSKA Moscow forward Vladislav Kamenev, formerly of the Colorado Avalanche, has been suspended for two years after testing positive for a performance-enhancing substance. Garrett states that the banned substance meldonium was detected in Kamenev’s sample as far back as March 2025. The suspension is expected to extend through the 2026-27 season, which also helps explain why Kamenev was unavailable to suit up for CSKA during the previous season.
Kamenev, now 29 years old, has been a notable contributor for CSKA Moscow, having helped the team secure two Gagarin Cup championships. His time in the NHL includes 66 regular-season games split between the Colorado Avalanche and the Nashville Predators, during which he recorded three goals and 13 points. The two-year ban marks a significant turn in Kamenev’s professional trajectory, casting a long shadow over his career with CSKA and his earlier NHL tenure.
The news has implications not only for Kamenev’s personal career but also for CSKA Moscow’s forward lineup, as the team would need to navigate the absence of a player with Kamenev’s experience and championship pedigree. The revelation of a positive meldonium test, a substance once used for various medical conditions but banned in contemporary professional sports, raises questions about the circumstances surrounding the case and the process that led to the suspension.
Kamenev’s suspension aligns with the broader patterns observed in professional hockey regarding anti-doping enforcement, where players facing performance-enhancing drug allegations can receive substantial suspensions that span multiple seasons. The two-year penalty, if upheld, will likely impact Kamenev’s long-term plans in European and North American leagues, potentially diminishing his opportunities to return to the NHL or to contend at the highest levels of international play for the duration of the ban.
From a performance perspective, Kamenev has demonstrated a solid track record with CSKA Moscow, contributing to their success during his tenure with the team. His past achievements, including two Gagarin Cup championships, underscore the value he has brought on the ice. The suspension, however, introduces uncertainty about his role and effectiveness upon his return, should he be eligible to resume competition after the ban concludes.
Fans and analysts are weighing the impact of this development on CSKA Moscow’s season-by-season competitiveness. With Kamenev sidelined through the 2026-27 season, the team will need to rely on other forwards to fill his minutes and production. The decision to suspend Kamenev for two years reflects the severity with which anti-doping violations are treated in professional hockey, emphasizing the sport’s commitment to maintaining fair play and integrity.
In reflecting on Kamenev’s career arc, it is clear that his on-ice achievements, including his time in the NHL and his success in the KHL, are now juxtaposed against the backdrop of a significant suspension. The long-term consequences of this ruling will depend on Kamenev’s ability to navigate the consequences of the ban, pursue potential avenues for reinstatement, and determine whether he can regain form and return to top-tier competition after his two-year absence.
As more details emerge, the hockey community will be watching closely to see how Kamenev addresses the setback, whether he appeals the decision, and how CSKA Moscow adjusts its roster strategy in response to this disciplinary action. The case serves as a reminder of the ongoing importance of compliance with anti-doping regulations and the lasting impact such violations can have on a player’s professional life and a team’s success.